BC PharmaCare is looking for your input on biosimilar etanercept (Erelzi) for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis and rheumatoid arthritis
Biosimilar etanercept (Erelzi) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide your input on biosimilar etanercept for the treatment of ankylosing spondylitis (AS), juvenile idiopathic arthritis (JIA) and rheumatoid arthritis (RA). You can give input if you are a B.C. resident and have AS, JIA or RA, a caregiver to someone with AS, JIA or RA, or if your group represents people who live with AS, JIA or RA.
Calling on the BC Government to save and change the lives of children living with systemic juvenile idiopathic arthritis.
Juvenile idiopathic arthritis (JIA) affects 24,000 infants to teens in BC and Canada, or 3 in every 1,000, making it one of the most common causes of chronic disability in children. Ten to 20 percent of children living with JIA have systemic juvenile idiopathic arthritis (sJIA), a severe and potentially life-threatening form of the disease. Both JIA and sJIA can be devastating and come with high financial, family and societal burdens.
In partnership with Arthritis Consumer Experts, Cassie and Friends Society is leading a call for the BC Government to drastically improve the outlook of children with sJIA by allowing reimbursement coverage for canakinumab for children who need it. For children who do not respond to other treatments, canakinumab can prevent progression of the disease and disease symptoms.
Cassie and Friends is urging all parties running for public office in British Columbia to make juvenile arthritis and canakinumab reimbursement access a health priority during the upcoming provincial election on May 9. You can help by sharing your story or sending an email or letter to your candidate. Together, we can help improve the lives of children living with arthritis!
What can you do? Continue reading
In honour of Juvenile Arthritis Awareness Month in Canada, we have compiled a list of interviews from this year’s CRA Annual Scientific Meeting & AHPA Annual Meeting in Ottawa. The interviews below highlight models of care, advocacy, clinical practices, and different therapy options for juvenile arthritis. Continue reading
MedPage Today interviewed specialists in rheumatology in the United States about the advances in rheumatology in 2016. Below are the five most common advances mentioned.
1. Tocilizumab (Actemra) for the treatment of giant cell arteritis
Giant cell arteritis affects over 200,000 people in the United States. Research data from an international clinical trial showed that after a year of treatment, 56% of the 250 study participants given tocilizumab weekly plus prednisone were in sustained remission, compared with just 14% of those given placebo alone (P<0.0001).
At the annual meeting of the American College of Rheumatology (ACR), Dr. John H. Stone of Harvard University at Boston noted: “There is something new in giant cell arteritis at last, and the era of unending glucocorticoid treatment with no viable alternative is over.” Continue reading
James Lowe is a New Zealand rugby union player and an official ambassador for Arthritis New Zealand. Lowe plays in the wing position for the Markos and Chiefs. In 2014, he played his first Super Rugby and contributed to the Chiefs 18-10 victory over the Crusaders in Christchurch. His aim is to play for the Kiwi World Cup squad in the near future.
Lowe was diagnosed with juvenile rheumatoid arthritis, also known as juvenile idiopathic arthritis (JIA), at the young age of 14. He takes prescribed medications and a weekly injection to control his arthritis. JIA strikes children under the age of 16 and affects an estimated one in 1000 children. It is one of the most common chronic diseases among children. To read about the different subtypes of juvenile idiopathic arthritis, please click here. Continue reading
State of Arthritis Medications: Some old, some new, all important
The reliable, quick reference arthritis medications guide you need to assist you and your health care team with your therapy conversations.
The JointHealth™ Medications Guide gives you information on the most commonly prescribed medications for inflammatory types of arthritis and osteoarthritis. Medication information for the following diseases is included in this year’s guide: rheumatoid arthritis, ankylosing spondylitis, juvenile arthritis, psoriatic arthritis, systemic lupus erythematosus, vasculitis, osteoarthritis, and osteoporosis.
In this JointHealth™ insight, you will also find:
- An explanation of the naming changes in the different categories of
- Insight into the patient-physician therapy conversation by Cheryl Koehn, Founder and President of Arthritis Consumer Experts
- Updated disease information for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile arthritis, and lupus
- The latest research on methotrexate and the consumption of alcoholic beverages